A small sample of the patient’s own tissue.
A small tissue sample is collected in the clinic. The preparation is autologous, starting directly from the patient’s own biological material.
Collect
A Lab-in-a-Box technology for tissue repair. Turning a small sample of a patient’s own tissue into a personalised topical preparation, inside the clinic.
A small sample of the patient’s own tissue, easily collected in the clinic.
100% automated preparation with a single-use proprietary consumable.
A personalised preparation, applied to the skin
Proposed workflow as a representation of the treatment. Details are confidential. Device images are concept renderings; people shown are illustrative.
The therapeutic efficacy of regenerative medicine is widely demonstrated. Bringing it into everyday clinical practice, however, presents three critical barriers:
Hands-on processing requires significant clinician time, specialized training, and leads to protocol variability between clinics.
Without automated protocols, achieving consistent, repeatable formulations across multiple centers is difficult to scale.
Traditional regenerative procedures rely heavily on injections, causing patient discomfort and limiting treatment adoption.
The Lab-in-a-Box is designed to take over the manual preparation, so a clinic can offer a personalised topical treatment from the patient’s own biology.
A small tissue sample is collected in the clinic. The preparation is autologous, starting directly from the patient’s own biological material.
Collect
The Lab-in-a-Box processes the sample automatically with a proprietary single-use kit. It is designed to reduce manual handling and keep every preparation consistent.
Process
The preparation is applied to the skin, without an injection. The first focus is regenerative aesthetics in premium clinics.
Apply
Proposed workflow. Device images are concept renderings; people shown are illustrative. The device is not yet commercially available.
Building the proprietary Lab-in-a-Box hardware and standardized preparation protocols.
Planned research milestone in collaboration with Vall d’Hebron Research Institute (VHIR).
Development of the patent portfolio and definition of the regulatory path through to CE marking.
This website presents technology currently in development and does not describe a product with CE certification. A preliminary regulatory assessment under EU MDR has been defined, and detailed regulatory pathways are shared confidentially with interested investors upon request.
The bottleneck in regenerative medicine is not biological: it is logistical and regulatory. REGEMED is designed to decouple autologous preparation from centralized infrastructure, with compact hardware and closed, recurring consumables, so a clinic can offer autologous treatments without a large investment in its own infrastructure.
Our technology, device architecture, and automated workflows are built around proprietary engineering and protected design strategies as we advance toward commercial deployment.
Device development is carried out in collaboration with a specialized externalized medical device engineering partner, ensuring industry-standard quality, ISO 13485 compliance, and efficient execution.
Contact the founders to request the investor deck and discuss the technology, the development plan, and the business model.
€76bn ~16% CAGR Global non-invasive & tissue care market, 2025. Projected €137bn by 2032.
€51bn ~34% CAGR Global regenerative medicine market, 2025. Projected €413bn by 2032.
REGEMED targets specialized clinics seeking a standardized, automated workflow for personalized autologous tissue preparation.
The automated Lab-in-a-Box technology is placed directly in the treatment room, bringing point-of-care processing to the clinic.
Each preparation uses a proprietary, single-use processing kit, establishing a scalable recurring model aligned with clinic volume.
Medical and business leadership from day one, with leading scientific advisors.

Co-founder & CEO
Leads business and finance.
Write to Olau
Co-founder & CMO
Leads medical and regulatory affairs.
Write to AleixAdvisory board
REGEMED is supported by specialists and experts in regenerative medicine, aging, and reconstructive surgery. Advisor credentials and clinical references are shared confidentially with verified investors.
CRAASH BarcelonaAcceleration programme
Horizon Deep Tech SummitTop 30 of 150+
Request the investor deck or schedule an introductory call with the founders. We will walk you through our technology, development roadmap, and investment opportunity.